Role of HE4 and ROMA Score in Diagnosis of Ovarian Cancer in Egyptian Women

Role of HE4 and ROMA Score in Diagnosis of Ovarian Cancer in Egyptian Women

Background: Risk of ovarian malignancy algorithm (ROMA) combining human epididymis secretory protein 4 (HE4) and CA125 is a novel score, specific for epithelial ovarian cancer (EOC). Method: Our cohort prospective study aimed to evaluate the role of HE4 and ROMA score in the diagnosis of EOC. We det...

Full description

Bibliographic Details
Main Authors:	Nahla El-Attar, Lamiaa Kamel, Amany Abdelghany, Rasha Haggag, Heba Taha, Entesar Mahdy, Nadia Madkour
Format:	Article
Language:	English
Published:	Shiraz University of Medical Sciences 2021-01-01
Series:	Middle East Journal of Cancer
Subjects:	ovarian cancer prognosis roma score ca125 he4
Online Access:	https://mejc.sums.ac.ir/article_46822_9288d8364ba401ebc576616e5a570654.pdf

Similar Items

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
by: Vincent Dochez, et al.
Published: (2019-03-01)

Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors
by: Núria Carreras-Dieguez, et al.
Published: (2022-01-01)

Evaluation of Human Epididymis Protein 4, Risk of Ovarian Malignancy Algorithm, and Risk of Malignancy Index Efficiency for Ameliorating Sensitivity and Specificity for Differentiating Benign from Malignant Adnexal Masses
by: Sonia Chawla, et al.

A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer
by: Diana Cviič, et al.
Published: (2023-03-01)

Molecular Biomarkers for the Early Detection of Ovarian Cancer
by: Ruiqian Zhang, et al.
Published: (2022-10-01)

Current clinical application of serum biomarkers to detect and monitor ovarian cancer – update
by: Łukasz Janas, et al.
Published: (2022-01-01)

The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer
by: Zheng Li-e, et al.
Published: (2016-01-01)

Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions
by: Artur Czekierdowski, et al.
Published: (2023-02-01)

Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms
by: Zixuan Song, et al.
Published: (2023-01-01)

Meigs’ syndrome with elevated CA-125 and HE-4: a case of luteinized fibrothecoma
by: Jaroslaw Danilos, et al.
Published: (2015-06-01)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients
by: Elham Saffarieh, et al.
Published: (2022-08-01)

HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect
by: Duanyang Liu, et al.
Published: (2018-06-01)

Correlation of Preoperative HE-4 and CA125 with Ovarian Cancer Staging in Ahvaz Imam Khomeni Hospital
by: Fatemeh Cheraghi, et al.
Published: (2020-01-01)

Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women
by: Aleksandra Gentry-Maharaj, et al.
Published: (2020-07-01)

Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
by: Yan Rong, et al.
Published: (2021-01-01)

HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients
by: Elena Ioana Braicu, et al.
Published: (2022-07-01)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
by: Chloe E. Barr, et al.
Published: (2023-02-01)

Assessment of levels of the tumor markers HE4 and CA125 considering staging, grading and histological types of endometrial cancer
by: Nabil Abdalla, et al.
Published: (2016-11-01)

Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer
by: Kelechi Njoku, et al.
Published: (2022-07-01)

Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer?
by: Aneta Cymbaluk-Płoska, et al.
Published: (2021-03-01)

Utility of Pelvic MRI and Tumor Markers HE4 and CA125 to Predict Depth of Myometrial Invasion and Cervical Involvement in Endometrial Cancer
by: Narges Zamani, et al.
Published: (2016-04-01)

HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial
by: Michel Fabbro, et al.
Published: (2024-01-01)

Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance
by: Yi-Chao Lee, et al.
Published: (2015-11-01)

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population
by: Chloe E. Barr, et al.
Published: (2022-04-01)

Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features
by: Chloe E. Barr, et al.
Published: (2022-11-01)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
by: Jorge A. Alegría-Baños, et al.
Published: (2021-07-01)

The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma
by: Sainan Gong, et al.
Published: (2023-07-01)

Effects of GnRH Agonist and Dienogest in Combination on HE4 and CA125 Levels in Patients with Adenomyosis and Adenomyoma: A Prospective Cohort Study
by: DongGe Wang, et al.
Published: (2023-07-01)

Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass
by: Khawla Al Musalhi, et al.
Published: (2016-09-01)

Biomarkers for Early Detection of Ovarian Cancer: A Review
by: Devarajappa Gari Bindu, et al.
Published: (2024-01-01)

Biomarkers towards Ovarian Cancer Diagnostics: Present and Future Prospects
by: Meenal Rastogi, et al.

Stacking Machine Learning Algorithms for Biomarker-Based Preoperative Diagnosis of a Pelvic Mass
by: Reid Shaw, et al.
Published: (2022-03-01)

High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer
by: Kalapotharakos Grigorios, et al.
Published: (2012-08-01)

Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified as Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules
by: Siew Fei Ngu, et al.
Published: (2022-02-01)

Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature
by: Miguel Ángel Elorriaga, et al.
Published: (2021-10-01)

Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy
by: Marcin Opławski, et al.
Published: (2022-08-01)

HE4 in the Diagnostic Approach of Endometrial Cancer in Patients with Postmenopausal Bleeding, the METRODEC Protocol: Protocol for a Multicenter Prospective Study
by: Manon Degez, et al.
Published: (2021-07-01)

Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study
by: Li-yuan Feng, et al.
Published: (2020-02-01)

Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma
by: Ankita Sethi, et al.
Published: (2022-04-01)

The Diagnostic Role of FGF 21 in Endometrial Cancer and Other Pathologies of the Uterine Corpus
by: Anna Jagodzińska, et al.
Published: (2023-01-01)